Kite Pharma Inc Cmn (KITE) 54.57 $KITE Kite Pha
Post# of 273254
Posted On: 09/24/2016 5:07:02 AM
Kite Pharma Inc Cmn (KITE) 54.57 $KITE
Kite Pharma Announces Exclusive License with the National Institutes of Health for Multiple Neoantigen Directed T-Cell Receptor (TCR) Product Candidates to Treat Solid Tumors Expressing Mutated KRAS
BusinessWire - Tue Sep 20, 3:05PM CDT
Kite Pharma, Inc. (Nasdaq:KITE), a clinical-stage biopharmaceutical company focused on developing engineered autologous T-cell therapy (eACT(TM)) products for the treatment of cancer, today announced that the Company has entered into an exclusive, worldwide license with the National Institutes of Health (NIH) for intellectual property related to multiple T-cell receptor (TCR) based product candidates for the treatment of tumors expressing mutated KRAS antigens.
KITE: 54.57 (-0.36)
Covered Call reports for Disney, Kite Pharma, Ford, CONSOL Energy and Caterpillar Inc. include trade ideas that offer returns of 20% or more!
PR Newswire - Fri Sep 16, 8:31AM CDT
InvestorsObserver issues critical PriceWatch Alerts for CAT, CNX, DIS, F, and KITE.
F: 12.17 (-0.01), CNX: 17.40 (-0.17), KITE: 54.57 (-0.36), DIS: 93.27 (-0.14), CAT: 82.44 (-1.06)
Research Reports Coverage on Biotech Stocks -- Northwest Biotherapeutics, Radius Health, Spectrum Pharma, and Kite Pharma
PR Newswire - Mon Sep 12, 7:05AM CDT
Biotechnology has seen some substantial declines since the start of this year due to political comments on pricing, which is expected to persist for an uncertain period of time. Some companies in the industry, however, signal recovery and growth potential given M&A activities and the development of new methodologies and platforms. This morning, Stock-Callers.com has initiated research reports on the following equities: Northwest Biotherapeutics Inc. (NASDAQ: NWBO), Radius Health Inc. (NASDAQ: RDUS), Spectrum Pharmaceuticals Inc. (NASDAQ: SPPI), and Kite Pharma Inc. (NASDAQ: KITE). These stocks research reports can be downloaded now by simply registering for free at:
RDUS: 56.52 (-0.89), NWBO: 0.53 (-0.02), KITE: 54.57 (-0.36), SPPI: 4.72 (-0.09)
Kite Pharma to Participate in September 2016 Investor Conferences
BusinessWire - Wed Aug 31, 3:05PM CDT
Kite Pharma, Inc., (Nasdaq:KITE) today announced that management will participate in a panel at the 11th Annual Citi Biotech Conference and a fireside chat discussion at the Morgan Stanley Global Healthcare Conference.
KITE: 54.57 (-0.36), MS: 31.91 (-0.33)
Oxis Biotech's TriKE Cancer-Fighting Technology Receives Key NIH Endorsement
ACCESSWIRE - Mon Aug 29, 6:30AM CDT
LOS ANGELES, CA / ACCESSWIRE / August 29, 2016 / Oxis Biotech Inc., a wholly owned subsidiary of Oxis International Inc. (OTCQB: OXIS and Euronext Paris OXI.PA), announced today that its research partners at the University of Minnesota cancer center are collaborating with the National Institutes of Health to accelerate commercialization of their promising TriKE cancer-fighting platform.
KITE: 54.57 (-0.36), JUNO: 30.11 (-0.51)
Kite Pharma Advisors and Scientific Pioneers in Cancer Immunotherapy Receive Prestigious Cellular Immune Therapy Award
BusinessWire - Fri Aug 19, 7:00AM CDT
Kite Pharma, Inc. (Nasdaq:KITE) today announced that two of its key advisors and scientific collaborators, both pioneers in the field of cancer immunotherapy, have received the renowned Novartis Prize for Clinical Immunology.
KITE: 54.57 (-0.36), NVS: 81.48 (-0.55)
Kite Pharma (KITE) Q2 Loss Wider but Focus is on KTE-C19
Arpita Dutt - Zacks Investment Research - Tue Aug 09, 5:44AM CDT
Although Kite's (KITE) Q2 loss was wider-than-expected, investor focus remains primarily on the company's progress with KTE-C19.
HSKA: 54.46 (-0.22), CBM: 46.60 (+0.30), KITE: 54.57 (-0.36), AMGN: 174.80 (-0.82)
Kite Pharma Reports Second Quarter 2016 Financial Results
BusinessWire - Mon Aug 08, 3:05PM CDT
--KTE-C19 Biologics License Application Filing Planned in Late 2016; Commercial Launch of KTE-C19 Expected in 2017
KITE: 54.57 (-0.36)
5 Drug Stocks Reporting Q2 Earnings on Aug 8: AGN & More
Zacks Equity Research - Zacks Investment Research - Fri Aug 05, 8:24AM CDT
As the Q2 earnings cycle draws to a close, the overall picture that has emerged does not appear as grim as we feared.
AGN: 243.94 (+0.51), ENDP: 23.39 (+3.13), JNJ: 118.81 (-0.65), RARE: 72.60 (-1.45), KITE: 54.57 (-0.36), HZNP: 19.43 (+0.02), NVS: 81.48 (-0.55)
Kite (KITE) Q2 Earnings: What's in Store for the Stock?
Arpita Dutt - Zacks Investment Research - Thu Aug 04, 5:56AM CDT
With Kite (KITE) being a development stage company, investor focus will remain on the company's pipeline updates and cash burn.
KITE: 54.57 (-0.36), INCY: 88.98 (-0.29), AMGN: 174.80 (-0.82), IONS: 35.12 (+0.10)
Kite Pharma to Present at the Canaccord Genuity 36th Annual Growth Conference
BusinessWire - Wed Aug 03, 3:16PM CDT
Kite Pharma, Inc., (Nasdaq:KITE) today announced that management will present at the Canaccord Genuity 36th Annual Growth Conference.
KITE: 54.57 (-0.36)
Kite Pharma to Report Second Quarter 2016 Financial Results on August 8, 2016
BusinessWire - Mon Aug 01, 3:05PM CDT
Kite Pharma, Inc. (Nasdaq:KITE) today announced that it will report second quarter 2016 financial results on Monday, August 8, 2016, after market close. The announcement will be followed by a live audio webcast and conference call at 4:30 PM Eastern Time (1:30 PM Pacific Time).
KITE: 54.57 (-0.36)
Oxis International Comments On New York Times Article About Cancer Immunotherapy
ACCESSWIRE - Mon Aug 01, 6:30AM CDT
LOS ANGELES, CA / ACCESSWIRE / August 1, 2016 / Oxis International Inc. (OTCQB: OXIS and Euronext Paris OXI.PA), a company that has made significant strides in harnessing the immune system to fight cancer, today commented on a New York Times article that examined cancer immunotherapy.
KITE: 54.57 (-0.36), JUNO: 30.11 (-0.51)
Kite Pharma Announces Exclusive License with the National Institutes of Health for Fully Human Anti-CD19 Chimeric Antigen Receptor (CAR) Product Candidate to Treat B-Cell Malignancies
BusinessWire - Wed Jul 27, 3:05PM CDT
Kite Pharma, Inc. (Nasdaq:KITE), a clinical-stage biopharmaceutical company focused on developing engineered autologous T-cell therapy (eACT(TM)) products for the treatment of cancer, today announced that the Company has entered into an exclusive, worldwide license with the National Institutes of Health (NIH) for intellectual property related to a fully human anti-CD19 chimeric antigen receptor-based product candidate directed against B-cell malignancies. The National Cancer Institute (NCI), with Dr. James N. Kochenderfer, M.D., an investigator in the Experimental Transplantation and Immunology Branch of the NCI, is currently conducting a Phase 1 clinical trial of the product candidate in patients with B-cell malignancies under an existing Cooperative Research and Development Agreement (CRADA) between Kite and the NCI.
KITE: 54.57 (-0.36)
Kite Pharma Opens State-of-the-Art T-Cell Therapy Manufacturing Facility
BusinessWire - Mon Jun 20, 3:55PM CDT
--Preparations on Track to Launch Lead Product Candidate KTE-C19 in 2017
KITE: 54.57 (-0.36)
Kite Pharma Expands Development of T-Cell Receptor (TCR) Therapies Targeting HPV-Associated Cancers in Partnership with the National Cancer Institute (NCI)
BusinessWire - Mon Jun 20, 7:05AM CDT
Kite Pharma, Inc. (NASDAQ:KITE) today announced that it has entered into a new Cooperative Research and Development Agreement (CRADA) with the Experimental Transplantation and Immunology Branch (ETIB) of the National Cancer Institute (NCI) for the research and clinical development of T-cell receptor (TCR) product candidates directed against human papillomavirus (HPV)-16 E6 and E7 oncoproteins for the treatment of HPV-associated cancers.
KITE: 54.57 (-0.36)
Kite Pharma to Highlight Key Data from CAR T-Cell Therapy Pipeline in Oral Presentations at the 2016 European Hematology Association (EHA) Annual Congress
BusinessWire - Wed Jun 08, 7:00AM CDT
--SCHOLAR-1, first meta-analysis of patient-level outcomes in chemorefractory DLBCL, an understudied patient population
KITE: 54.57 (-0.36)
Stock Market News for June 07, 2016
Zacks Equity Research - Zacks Investment Research - Tue Jun 07, 9:10AM CDT
Benchmarks closed in the green on Monday after the Fed Chairwoman Janet Yellen said that most of the domestic economic data were favorable and indicated rate hikes this year.
VRTX: 90.63 (-1.49), FCX: 10.63 (-0.35), ILMN: 179.33 (-0.01), XOM: 83.45 (-0.09), MYL: 42.06 (-0.53), BA: 131.78 (-0.09), SLB: 75.92 (-1.09), AA: 9.76 (-0.02), LYB: 77.39 (-0.79), RIG: 9.10 (-0.55), KITE: 54.57 (-0.36), CF: 22.63 (-0.60), CHK: 6.63 (-0.24), EOG: 89.75 (-2.86), CVX: 99.22 (-0.76), ECL: 119.04 (-0.10)
Why is Kite Pharma (KITE) Stock Soaring Today?
Madeleine Johnson - Zacks Investment Research - Mon Jun 06, 3:42PM CDT
On Monday, shares of clinical-stage biopharmaceutical company Kite Pharma Inc. (KITE) are soaring, up over 12% in afternoon trading after the company announced results from SCHOLAR-1 (Retrospective Non-Hodgkin Lymphoma Research).
KITE: 54.57 (-0.36)
Kite Pharma Announces the First Meta-Analysis of Outcomes in Chemorefractory Diffuse Large B-Cell Lymphoma (SCHOLAR-1)
BusinessWire - Mon Jun 06, 6:45AM CDT
--Overall response rate was 26% with only 8% achieving a complete response
KITE: 54.57 (-0.36)
Kite Pharma Announces Exclusive License with the National Institutes of Health for Multiple Neoantigen Directed T-Cell Receptor (TCR) Product Candidates to Treat Solid Tumors Expressing Mutated KRAS
BusinessWire - Tue Sep 20, 3:05PM CDT
Kite Pharma, Inc. (Nasdaq:KITE), a clinical-stage biopharmaceutical company focused on developing engineered autologous T-cell therapy (eACT(TM)) products for the treatment of cancer, today announced that the Company has entered into an exclusive, worldwide license with the National Institutes of Health (NIH) for intellectual property related to multiple T-cell receptor (TCR) based product candidates for the treatment of tumors expressing mutated KRAS antigens.
KITE: 54.57 (-0.36)
Covered Call reports for Disney, Kite Pharma, Ford, CONSOL Energy and Caterpillar Inc. include trade ideas that offer returns of 20% or more!
PR Newswire - Fri Sep 16, 8:31AM CDT
InvestorsObserver issues critical PriceWatch Alerts for CAT, CNX, DIS, F, and KITE.
F: 12.17 (-0.01), CNX: 17.40 (-0.17), KITE: 54.57 (-0.36), DIS: 93.27 (-0.14), CAT: 82.44 (-1.06)
Research Reports Coverage on Biotech Stocks -- Northwest Biotherapeutics, Radius Health, Spectrum Pharma, and Kite Pharma
PR Newswire - Mon Sep 12, 7:05AM CDT
Biotechnology has seen some substantial declines since the start of this year due to political comments on pricing, which is expected to persist for an uncertain period of time. Some companies in the industry, however, signal recovery and growth potential given M&A activities and the development of new methodologies and platforms. This morning, Stock-Callers.com has initiated research reports on the following equities: Northwest Biotherapeutics Inc. (NASDAQ: NWBO), Radius Health Inc. (NASDAQ: RDUS), Spectrum Pharmaceuticals Inc. (NASDAQ: SPPI), and Kite Pharma Inc. (NASDAQ: KITE). These stocks research reports can be downloaded now by simply registering for free at:
RDUS: 56.52 (-0.89), NWBO: 0.53 (-0.02), KITE: 54.57 (-0.36), SPPI: 4.72 (-0.09)
Kite Pharma to Participate in September 2016 Investor Conferences
BusinessWire - Wed Aug 31, 3:05PM CDT
Kite Pharma, Inc., (Nasdaq:KITE) today announced that management will participate in a panel at the 11th Annual Citi Biotech Conference and a fireside chat discussion at the Morgan Stanley Global Healthcare Conference.
KITE: 54.57 (-0.36), MS: 31.91 (-0.33)
Oxis Biotech's TriKE Cancer-Fighting Technology Receives Key NIH Endorsement
ACCESSWIRE - Mon Aug 29, 6:30AM CDT
LOS ANGELES, CA / ACCESSWIRE / August 29, 2016 / Oxis Biotech Inc., a wholly owned subsidiary of Oxis International Inc. (OTCQB: OXIS and Euronext Paris OXI.PA), announced today that its research partners at the University of Minnesota cancer center are collaborating with the National Institutes of Health to accelerate commercialization of their promising TriKE cancer-fighting platform.
KITE: 54.57 (-0.36), JUNO: 30.11 (-0.51)
Kite Pharma Advisors and Scientific Pioneers in Cancer Immunotherapy Receive Prestigious Cellular Immune Therapy Award
BusinessWire - Fri Aug 19, 7:00AM CDT
Kite Pharma, Inc. (Nasdaq:KITE) today announced that two of its key advisors and scientific collaborators, both pioneers in the field of cancer immunotherapy, have received the renowned Novartis Prize for Clinical Immunology.
KITE: 54.57 (-0.36), NVS: 81.48 (-0.55)
Kite Pharma (KITE) Q2 Loss Wider but Focus is on KTE-C19
Arpita Dutt - Zacks Investment Research - Tue Aug 09, 5:44AM CDT
Although Kite's (KITE) Q2 loss was wider-than-expected, investor focus remains primarily on the company's progress with KTE-C19.
HSKA: 54.46 (-0.22), CBM: 46.60 (+0.30), KITE: 54.57 (-0.36), AMGN: 174.80 (-0.82)
Kite Pharma Reports Second Quarter 2016 Financial Results
BusinessWire - Mon Aug 08, 3:05PM CDT
--KTE-C19 Biologics License Application Filing Planned in Late 2016; Commercial Launch of KTE-C19 Expected in 2017
KITE: 54.57 (-0.36)
5 Drug Stocks Reporting Q2 Earnings on Aug 8: AGN & More
Zacks Equity Research - Zacks Investment Research - Fri Aug 05, 8:24AM CDT
As the Q2 earnings cycle draws to a close, the overall picture that has emerged does not appear as grim as we feared.
AGN: 243.94 (+0.51), ENDP: 23.39 (+3.13), JNJ: 118.81 (-0.65), RARE: 72.60 (-1.45), KITE: 54.57 (-0.36), HZNP: 19.43 (+0.02), NVS: 81.48 (-0.55)
Kite (KITE) Q2 Earnings: What's in Store for the Stock?
Arpita Dutt - Zacks Investment Research - Thu Aug 04, 5:56AM CDT
With Kite (KITE) being a development stage company, investor focus will remain on the company's pipeline updates and cash burn.
KITE: 54.57 (-0.36), INCY: 88.98 (-0.29), AMGN: 174.80 (-0.82), IONS: 35.12 (+0.10)
Kite Pharma to Present at the Canaccord Genuity 36th Annual Growth Conference
BusinessWire - Wed Aug 03, 3:16PM CDT
Kite Pharma, Inc., (Nasdaq:KITE) today announced that management will present at the Canaccord Genuity 36th Annual Growth Conference.
KITE: 54.57 (-0.36)
Kite Pharma to Report Second Quarter 2016 Financial Results on August 8, 2016
BusinessWire - Mon Aug 01, 3:05PM CDT
Kite Pharma, Inc. (Nasdaq:KITE) today announced that it will report second quarter 2016 financial results on Monday, August 8, 2016, after market close. The announcement will be followed by a live audio webcast and conference call at 4:30 PM Eastern Time (1:30 PM Pacific Time).
KITE: 54.57 (-0.36)
Oxis International Comments On New York Times Article About Cancer Immunotherapy
ACCESSWIRE - Mon Aug 01, 6:30AM CDT
LOS ANGELES, CA / ACCESSWIRE / August 1, 2016 / Oxis International Inc. (OTCQB: OXIS and Euronext Paris OXI.PA), a company that has made significant strides in harnessing the immune system to fight cancer, today commented on a New York Times article that examined cancer immunotherapy.
KITE: 54.57 (-0.36), JUNO: 30.11 (-0.51)
Kite Pharma Announces Exclusive License with the National Institutes of Health for Fully Human Anti-CD19 Chimeric Antigen Receptor (CAR) Product Candidate to Treat B-Cell Malignancies
BusinessWire - Wed Jul 27, 3:05PM CDT
Kite Pharma, Inc. (Nasdaq:KITE), a clinical-stage biopharmaceutical company focused on developing engineered autologous T-cell therapy (eACT(TM)) products for the treatment of cancer, today announced that the Company has entered into an exclusive, worldwide license with the National Institutes of Health (NIH) for intellectual property related to a fully human anti-CD19 chimeric antigen receptor-based product candidate directed against B-cell malignancies. The National Cancer Institute (NCI), with Dr. James N. Kochenderfer, M.D., an investigator in the Experimental Transplantation and Immunology Branch of the NCI, is currently conducting a Phase 1 clinical trial of the product candidate in patients with B-cell malignancies under an existing Cooperative Research and Development Agreement (CRADA) between Kite and the NCI.
KITE: 54.57 (-0.36)
Kite Pharma Opens State-of-the-Art T-Cell Therapy Manufacturing Facility
BusinessWire - Mon Jun 20, 3:55PM CDT
--Preparations on Track to Launch Lead Product Candidate KTE-C19 in 2017
KITE: 54.57 (-0.36)
Kite Pharma Expands Development of T-Cell Receptor (TCR) Therapies Targeting HPV-Associated Cancers in Partnership with the National Cancer Institute (NCI)
BusinessWire - Mon Jun 20, 7:05AM CDT
Kite Pharma, Inc. (NASDAQ:KITE) today announced that it has entered into a new Cooperative Research and Development Agreement (CRADA) with the Experimental Transplantation and Immunology Branch (ETIB) of the National Cancer Institute (NCI) for the research and clinical development of T-cell receptor (TCR) product candidates directed against human papillomavirus (HPV)-16 E6 and E7 oncoproteins for the treatment of HPV-associated cancers.
KITE: 54.57 (-0.36)
Kite Pharma to Highlight Key Data from CAR T-Cell Therapy Pipeline in Oral Presentations at the 2016 European Hematology Association (EHA) Annual Congress
BusinessWire - Wed Jun 08, 7:00AM CDT
--SCHOLAR-1, first meta-analysis of patient-level outcomes in chemorefractory DLBCL, an understudied patient population
KITE: 54.57 (-0.36)
Stock Market News for June 07, 2016
Zacks Equity Research - Zacks Investment Research - Tue Jun 07, 9:10AM CDT
Benchmarks closed in the green on Monday after the Fed Chairwoman Janet Yellen said that most of the domestic economic data were favorable and indicated rate hikes this year.
VRTX: 90.63 (-1.49), FCX: 10.63 (-0.35), ILMN: 179.33 (-0.01), XOM: 83.45 (-0.09), MYL: 42.06 (-0.53), BA: 131.78 (-0.09), SLB: 75.92 (-1.09), AA: 9.76 (-0.02), LYB: 77.39 (-0.79), RIG: 9.10 (-0.55), KITE: 54.57 (-0.36), CF: 22.63 (-0.60), CHK: 6.63 (-0.24), EOG: 89.75 (-2.86), CVX: 99.22 (-0.76), ECL: 119.04 (-0.10)
Why is Kite Pharma (KITE) Stock Soaring Today?
Madeleine Johnson - Zacks Investment Research - Mon Jun 06, 3:42PM CDT
On Monday, shares of clinical-stage biopharmaceutical company Kite Pharma Inc. (KITE) are soaring, up over 12% in afternoon trading after the company announced results from SCHOLAR-1 (Retrospective Non-Hodgkin Lymphoma Research).
KITE: 54.57 (-0.36)
Kite Pharma Announces the First Meta-Analysis of Outcomes in Chemorefractory Diffuse Large B-Cell Lymphoma (SCHOLAR-1)
BusinessWire - Mon Jun 06, 6:45AM CDT
--Overall response rate was 26% with only 8% achieving a complete response
KITE: 54.57 (-0.36)
(0)
(0)Scroll down for more posts ▼